Fujian Cancer Hospital Registers Clinical Trial for Sacituzumab Tirumotecan in Cervical Cancer Treatment

Strategic Insights -

Fujian Cancer Hospital has initiated a clinical trial to investigate the efficacy and safety of Sacituzumab Tirumotecan (SacTMT/SKB264) in combination with Iparomlimab/Tuvonralimab (QL1706) as a second-line or later therapy for patients with recurrent or metastatic cervical cancer. The study, registered with the Chinese Clinical Trial Registry (ChiCTR) under number ChiCTR2500111257, aims to evaluate the objective response rate, overall survival, progression-free survival, disease control rate, and duration of response in this patient population. Additionally, the trial will explore the association between TROP2 expression and clinical efficacy, as well as the relationship between tumor immune microenvironment features and clinical efficacy.

Key Takeaways:

  • The clinical trial, ChiCTR2500111257, is an interventional study aimed at evaluating the efficacy and safety of Sacituzumab Tirumotecan (SacTMT/SKB264) in combination with Iparomlimab/Tuvonralimab (QL1706) for cervical cancer patients.
  • The primary objective of the study is to evaluate the objective response rate (ORR) of the combination in patients with recurrent or metastatic cervical cancer.
  • Secondary objectives include evaluating overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and duration of response (DoR).
  • Exploratory objectives include examining the association between TROP2 expression and clinical efficacy, as well as the relationship between tumor immune microenvironment features and clinical efficacy.
  • The study will enroll patients with recurrent or metastatic cervical cancer, including squamous cell carcinoma and non-squamous histologies.
  • The combination of Sacituzumab Tirumotecan and Iparomlimab/Tuvonralimab is being explored as a potential new treatment option for patients with advanced cervical cancer.

Statistics:

  • ChiCTR2500111257 is the registration number of the clinical trial.
  • The study type is Interventional.
  • The full-text of the clinical trial can be found at the Chinese Clinical Trial Registry website.

Sources:

  • Chinese Clinical Trial Registry (ChiCTR)
  • https://www.chictr.org.cn/showprojEN.html?proj=281161
  • Chinese Clinical Trial Registry, ChiCTR2500111257, accessed on [exact date not provided].